Form 4 for ADCT ADC Therapeutics SA
Accepted 2025-05-19 00:00:00 ET · period of report 2025-05-15 · accession 0001731122-25-000779 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-19 | 2025-05-15 | ADCT | WILD HANS PETER | 10% | J - Other | — | +9.79M | 9.79M | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-05-15 | J | A | 9,788,944 | — | 9,788,944 | D | — | — | (F1) Dr. Hans-Peter Wild ("Dr. Wild") holds a portion of the shares directly and another portion indirectly via HP Wild Holding AG ("HPW Holding") and HPWH TH AG ("HPWH"). The principal business of HPWH is holding investment rights in, directly or indirectly, ADCT. HPW Holding is an intermediary holding company and Dr. Wild is the Chairman of HPW Holding and HPWH. Thomas Pfisterer was a member of the Board of HPWH and held a total of 451,856 shares directly or indirectly in HPWH, but has transferred such ownership by way of an intragroup sale following Thomas Pfisterer stepping down from the Board of HPWH. |